A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma

Valentina Borghi, Elena Bastia, Massimiliano Guzzetta, Valerio Chiroli, Carol B Toris, Minerva R. Batugo, Samantha T. Carreiro, Wesley K M Chong, David C. Gale, David J. Kucera, Liu Jia, Ganesh Prasanna, Ennio Ongini, Achim H P Krauss, Francesco Impagnatiello

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular aqueous humor dynamics by targeting mechanisms that are complementary to those of prostaglandins. Here, we have characterized a newly synthesized compound, NCX 125, comprising latanoprost acid and NO-donating moieties. Methods: NCX 125 was synthesized and tested in vitro for its ability to release functionally active NO and then compared with core latanoprost for its intraocular pressure (IOP)-lowering effects in rabbit, dog, and nonhuman primate models of glaucoma. Results: NCX 125 elicited cGMP formation (EC 50 = 3.8 ± 1.0 μM) in PC12 cells and exerted NO-dependent iNOS inhibition (IC50 = 55 ± 11 μM) in RAW 264.7 macrophages. NCX 125 lowered IOP to a greater extent compared with equimolar latanoprost in: (a) rabbit model of transient ocular hypertension (0.030% latanoprost, not effective; 0.039% NCX 125, Δmax =-10.6 ± 2.3 mm Hg), (b) ocular hypertensive glaucomatous dogs (0.030% latanoprost, Δmax=-6.7 ± 1.2 mm Hg; 0.039% NCX 125, Δmax =-9.1 ± 3.1 mm Hg), and (c) laser-induced ocular hypertensive non-human primates (0.10% latanoprost, Δmax =-11.9 ± 3.7 mm Hg, 0.13% NCX 125, Δmax =-16.7 ± 2.2 mm Hg). In pharmacokinetic studies, NCX 125 and latanoprost resulted in similar latanoprost-free acid exposure in anterior segment ocular tissues. Conclusions: NCX 125, a compound targeting 2 different mechanisms, is endowed with potent ocular hypotensive effects. This may lead to potential new perspectives in the treatment of patients at risk of glaucoma.

Original languageEnglish (US)
Pages (from-to)125-131
Number of pages7
JournalJournal of Ocular Pharmacology and Therapeutics
Volume26
Issue number2
DOIs
StatePublished - Apr 1 2010

Fingerprint

latanoprost
Synthetic Prostaglandins
Intraocular Pressure
Glaucoma
Primates
Nitric Oxide
Dogs
Rabbits
Ocular Physiological Phenomena
1-(nitrooxymethyl)-2-(nitrooxy)ethyl 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Ocular Hypertension
Acids
Aqueous Humor
PC12 Cells

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. / Borghi, Valentina; Bastia, Elena; Guzzetta, Massimiliano; Chiroli, Valerio; Toris, Carol B; Batugo, Minerva R.; Carreiro, Samantha T.; Chong, Wesley K M; Gale, David C.; Kucera, David J.; Jia, Liu; Prasanna, Ganesh; Ongini, Ennio; Krauss, Achim H P; Impagnatiello, Francesco.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 26, No. 2, 01.04.2010, p. 125-131.

Research output: Contribution to journalArticle

Borghi, V, Bastia, E, Guzzetta, M, Chiroli, V, Toris, CB, Batugo, MR, Carreiro, ST, Chong, WKM, Gale, DC, Kucera, DJ, Jia, L, Prasanna, G, Ongini, E, Krauss, AHP & Impagnatiello, F 2010, 'A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma', Journal of Ocular Pharmacology and Therapeutics, vol. 26, no. 2, pp. 125-131. https://doi.org/10.1089/jop.2009.0120
Borghi, Valentina ; Bastia, Elena ; Guzzetta, Massimiliano ; Chiroli, Valerio ; Toris, Carol B ; Batugo, Minerva R. ; Carreiro, Samantha T. ; Chong, Wesley K M ; Gale, David C. ; Kucera, David J. ; Jia, Liu ; Prasanna, Ganesh ; Ongini, Ennio ; Krauss, Achim H P ; Impagnatiello, Francesco. / A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. In: Journal of Ocular Pharmacology and Therapeutics. 2010 ; Vol. 26, No. 2. pp. 125-131.
@article{77e61b0136134d7783529aafca83f24a,
title = "A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma",
abstract = "Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular aqueous humor dynamics by targeting mechanisms that are complementary to those of prostaglandins. Here, we have characterized a newly synthesized compound, NCX 125, comprising latanoprost acid and NO-donating moieties. Methods: NCX 125 was synthesized and tested in vitro for its ability to release functionally active NO and then compared with core latanoprost for its intraocular pressure (IOP)-lowering effects in rabbit, dog, and nonhuman primate models of glaucoma. Results: NCX 125 elicited cGMP formation (EC 50 = 3.8 ± 1.0 μM) in PC12 cells and exerted NO-dependent iNOS inhibition (IC50 = 55 ± 11 μM) in RAW 264.7 macrophages. NCX 125 lowered IOP to a greater extent compared with equimolar latanoprost in: (a) rabbit model of transient ocular hypertension (0.030{\%} latanoprost, not effective; 0.039{\%} NCX 125, Δmax =-10.6 ± 2.3 mm Hg), (b) ocular hypertensive glaucomatous dogs (0.030{\%} latanoprost, Δmax=-6.7 ± 1.2 mm Hg; 0.039{\%} NCX 125, Δmax =-9.1 ± 3.1 mm Hg), and (c) laser-induced ocular hypertensive non-human primates (0.10{\%} latanoprost, Δmax =-11.9 ± 3.7 mm Hg, 0.13{\%} NCX 125, Δmax =-16.7 ± 2.2 mm Hg). In pharmacokinetic studies, NCX 125 and latanoprost resulted in similar latanoprost-free acid exposure in anterior segment ocular tissues. Conclusions: NCX 125, a compound targeting 2 different mechanisms, is endowed with potent ocular hypotensive effects. This may lead to potential new perspectives in the treatment of patients at risk of glaucoma.",
author = "Valentina Borghi and Elena Bastia and Massimiliano Guzzetta and Valerio Chiroli and Toris, {Carol B} and Batugo, {Minerva R.} and Carreiro, {Samantha T.} and Chong, {Wesley K M} and Gale, {David C.} and Kucera, {David J.} and Liu Jia and Ganesh Prasanna and Ennio Ongini and Krauss, {Achim H P} and Francesco Impagnatiello",
year = "2010",
month = "4",
day = "1",
doi = "10.1089/jop.2009.0120",
language = "English (US)",
volume = "26",
pages = "125--131",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma

AU - Borghi, Valentina

AU - Bastia, Elena

AU - Guzzetta, Massimiliano

AU - Chiroli, Valerio

AU - Toris, Carol B

AU - Batugo, Minerva R.

AU - Carreiro, Samantha T.

AU - Chong, Wesley K M

AU - Gale, David C.

AU - Kucera, David J.

AU - Jia, Liu

AU - Prasanna, Ganesh

AU - Ongini, Ennio

AU - Krauss, Achim H P

AU - Impagnatiello, Francesco

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular aqueous humor dynamics by targeting mechanisms that are complementary to those of prostaglandins. Here, we have characterized a newly synthesized compound, NCX 125, comprising latanoprost acid and NO-donating moieties. Methods: NCX 125 was synthesized and tested in vitro for its ability to release functionally active NO and then compared with core latanoprost for its intraocular pressure (IOP)-lowering effects in rabbit, dog, and nonhuman primate models of glaucoma. Results: NCX 125 elicited cGMP formation (EC 50 = 3.8 ± 1.0 μM) in PC12 cells and exerted NO-dependent iNOS inhibition (IC50 = 55 ± 11 μM) in RAW 264.7 macrophages. NCX 125 lowered IOP to a greater extent compared with equimolar latanoprost in: (a) rabbit model of transient ocular hypertension (0.030% latanoprost, not effective; 0.039% NCX 125, Δmax =-10.6 ± 2.3 mm Hg), (b) ocular hypertensive glaucomatous dogs (0.030% latanoprost, Δmax=-6.7 ± 1.2 mm Hg; 0.039% NCX 125, Δmax =-9.1 ± 3.1 mm Hg), and (c) laser-induced ocular hypertensive non-human primates (0.10% latanoprost, Δmax =-11.9 ± 3.7 mm Hg, 0.13% NCX 125, Δmax =-16.7 ± 2.2 mm Hg). In pharmacokinetic studies, NCX 125 and latanoprost resulted in similar latanoprost-free acid exposure in anterior segment ocular tissues. Conclusions: NCX 125, a compound targeting 2 different mechanisms, is endowed with potent ocular hypotensive effects. This may lead to potential new perspectives in the treatment of patients at risk of glaucoma.

AB - Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular aqueous humor dynamics by targeting mechanisms that are complementary to those of prostaglandins. Here, we have characterized a newly synthesized compound, NCX 125, comprising latanoprost acid and NO-donating moieties. Methods: NCX 125 was synthesized and tested in vitro for its ability to release functionally active NO and then compared with core latanoprost for its intraocular pressure (IOP)-lowering effects in rabbit, dog, and nonhuman primate models of glaucoma. Results: NCX 125 elicited cGMP formation (EC 50 = 3.8 ± 1.0 μM) in PC12 cells and exerted NO-dependent iNOS inhibition (IC50 = 55 ± 11 μM) in RAW 264.7 macrophages. NCX 125 lowered IOP to a greater extent compared with equimolar latanoprost in: (a) rabbit model of transient ocular hypertension (0.030% latanoprost, not effective; 0.039% NCX 125, Δmax =-10.6 ± 2.3 mm Hg), (b) ocular hypertensive glaucomatous dogs (0.030% latanoprost, Δmax=-6.7 ± 1.2 mm Hg; 0.039% NCX 125, Δmax =-9.1 ± 3.1 mm Hg), and (c) laser-induced ocular hypertensive non-human primates (0.10% latanoprost, Δmax =-11.9 ± 3.7 mm Hg, 0.13% NCX 125, Δmax =-16.7 ± 2.2 mm Hg). In pharmacokinetic studies, NCX 125 and latanoprost resulted in similar latanoprost-free acid exposure in anterior segment ocular tissues. Conclusions: NCX 125, a compound targeting 2 different mechanisms, is endowed with potent ocular hypotensive effects. This may lead to potential new perspectives in the treatment of patients at risk of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=77951672920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951672920&partnerID=8YFLogxK

U2 - 10.1089/jop.2009.0120

DO - 10.1089/jop.2009.0120

M3 - Article

VL - 26

SP - 125

EP - 131

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 2

ER -